Loading patent…
AssigneeThe Trustees of the University of Pennsylvania
InventorsChristopher A. Hunter, Anthony T. Phan, Mohamad-Gabriel Alameh, Drew Weissman, Emily Anne Aunins
Estimating the term…
The invention includes lipid nanoparticles (LNP) capable of eliciting a modulated immune response against an antigen in a subject. The LNPs comprise: (a) at least one first nucleoside-modified ribonucleic acid (RNA) encoding an antigen; (b) at least one second nucleoside-modified RNA encoding a cytokine or immune receptor (such as but not limited to a cytokine receptor); and (c) at least one ionizable lipid. The invention also includes pharmaceutical compositions comprising the LNP of the invention, as well as a method of eliciting a modulated immune response against an antigen in a subject, the method comprising administering an effective amount of a pharmaceutical compositions comprising the LNP of the invention.
A lipid nanoparticle (LNP), wherein the LNP comprises:
(canceled)
5-6. (canceled)
8-9. (canceled)
11-13. (canceled)
15-16. (canceled)
18-20. (canceled)
(canceled)
A method of eliciting a modulated immune response against an antigen in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a lipid nanoparticle (LNP) and at least one pharmaceutically acceptable carrier, diluent, or excipient, wherein the LNP comprises:
(canceled)
29-30. (canceled)
32-33. (canceled)
35-37. (canceled)
39-40. (canceled)
42-44. (canceled)
48-50. (canceled)
Dependencies are inferred from the claim text.